Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2021 | Where is the follicular lymphoma space moving?

Krish Patel • 3 Jun 2021
EHA 2021
Follicular Lymphoma Lymphoma Axicabtagene ciloleucel CAR-T Tazemetostat Umbralisib

Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, discussess the latest developments in the field of follicular lymphoma, highlighting the approval of the chimeric antigen receptor T-cell (CAR-T) therapy axicabtagene ciloleucel, the EZH2 inhibitor tazemetostat, and the novel PI3K inhibitor umbralisib. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Krish Patel

Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Durability of responses in patients with DLBCL treated with liso-cel: real-world insights 0:48
Durability of responses in patients with DLBCL treated with liso-cel: real-world insights
Krish Patel • 4 Sep 2025
The potential of NK cell-based therapies for B-cell lymphomas 1:01
The potential of NK cell-based therapies for B-cell lymphomas
Krish Patel • 5 Sep 2025
Treating MCL after covalent BTKi: CAR T-cells, non-covalent BTKi, antibody-drug conjugates, & more 1:25
Treating MCL after covalent BTKi: CAR T-cells, non-covalent BTKi, antibody-drug conjugates, & more
Krish Patel • 5 Sep 2025

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals